GCV Asia Congress 2018
Skip Content

5 October 2017

Palleon pals with corporates for series A

SR One, where the cancer drug developer was incubated, joined fellow corporate venturing units AbbVie Ventures, Pfizer Ventures and Takeda Ventures for a $47.6m round.

Author: Sam McCaffrey, Reporter

SR One, the investment arm of pharmaceutical firm GlaxoSmithKline (GSK), has led and syndicated a $47.6m series A round for US-based oncology drug developer Palleon Pharmaceuticals that closed yesterday.